About this document

Cipla by Rohan Paunikar is a document available to read on EtoBox.

Cipla is analyzing three potential anti-microbial/allergy drug projects - Terfenadine, Cetrizine, and Chlorpheniramine - to determine which has the most positive cash flow. Over 1 billion people suffer from fungal and other allergies globally. The anti-fungal drug market is large at $6 billion due to increased resistance and side effects of current therapies. NPV is calculated using a 12.56% discount rate and future cash flows to evaluate project profitability. Terfenadine has a negative NPV while Cetrizine

Author

Rohan Paunikar

Language

EN